**Supplemental Digital Content 6.** Proportion of participants who achieved an hSBA vaccine seroresponse\* at Day 30 by age group (Per Protocol Analysis Set).

|  |  |  |  |
| --- | --- | --- | --- |
| **Serogroups** | **MenACYW-TT****(N=458)** | **MenACWY-CRM****(N=460)** | **MenACYW-TT–** **MenACWY-CRM** |
|  | **n/M** | **% (95% CI)** | **n/M** | **% (95% CI)** | **Difference, % (95% CI)** |
| **2–5 years** |  |  |  |  |  |
| **A** | 119/227 | 52.4 (45.7, 59.1) | 99/221 | 44.8 (38.1, 51.6) | 7.6 (–1.6, 16.7) |
| **C** | 216/229 | 94.3 (90.5, 96.9) | 96/222 | 43.2 (36.6, 50.0) | 51.1 (43.5, 57.8) |
| **W** | 169/229 | 73.8 (67.6, 79.4) | 136/222 | 61.3 (54.5, 67.7) | 12.5 (3.9, 20.9) |
| **Y** | 202/229 | 88.2 (83.3, 92.1) | 171/222 | 77.0 (70.9, 82.4) | 11.2 (4.2, 18.1) |
| **6–9 years** |  |  |  |  |  |
| **A** | 133/228 | 58.3 (51.6, 64.8) | 120/237 | 50.6 (44.1, 57.2) | 7.7 (–1.3, 16.6) |
| **C** | 220/229 | 96.1 (92.7, 98.2) | 123/236 | 52.1 (45.5, 58.6) | 44.0 (36.8, 50.6) |
| **W** | 192/229 | 83.8 (78.4, 88.4) | 158/237 | 66.7 (60.3, 72.6) | 17.2 (9.4, 24.7) |
| **Y** | 217/229 | 94.8 (91.0, 97.3) | 193/237 | 81.4 (75.9, 86.2) | 13.3 (7.6, 19.2) |

CI, confidence interval; GMTs, geometric mean titers; GMTR, GMT ratio; M, number of participants with available data for the endpoint; n, number of participants who experienced an hSBA vaccine seroresponse.

\*hSBA vaccine seroresponse was demonstrated if a participant had pre-vaccination titers <1:8, then the post-vaccination titer had to be ≥1:16, or for a participant with a pre-vaccination titer ≥1:8, the post-vaccination titer had to be at least 4-fold greater than the pre-vaccination titer; 95% CIs of the single proportion was calculated from the exact binomial method.